Hemab Raises $157m To Take Lead Bleeding Disorder Drug Into Pivotal Trial

 
• By Mandy Jackson
  
Hemab will take sutacimig into a pivotal trial in Glanzmann thrombasthenia and deliver Phase II data in Factor VII deficiency in 2026 (Shutterstock)

More from Scrip

More from Financing